Comparing intermittent fasting and daily calorie cutting on sleep, body measurements, and composition in overweight women

This is a randomized, controlled, parallel-group trial to compare the effect of a modified intermittent fasting diet and daily calorie restriction diet on sleep quality and anthropometric indices in women with obesity or overweight over 8 weeks. The framework of the trial is superiority. Participants will be selected from the Health Centers of Kashan University of Medical Sciences by simple random sampling. Participants will be randomly assigned into two groups, daily calorie restriction (control) and fasting (intervention). The protocol was approved by the Ethics Committee of Kashan University of Medical Sciences (IR.KAUMS.MEDNT.REC.1401.046) and was registered at the Iranian Registry of Clinical Trials (IRCT20220522054958N3). All participants will give written consent before any study-related procedure. Inclusion criteria include obese or overweight (40 >BMI ≥25) women between 18 and 50 years old. Exclusion criteria include breastfeeding; pregnancy; having chronic diseases such as heart disease, hypertension, diabetes, and gastrointestinal disorders; smoking; weight loss of 1 to 2 kg in the past month; alcohol abuse; following a specific diet or taking a specific medication; overnight shifts; taking dietary supplements; and having mental or psychological diseases. The obese or overweight (40 >BMI ≥25) women between 18 and 50 years old will be included in the study, provided they meet the inclusion criteria.

Fifty-six participants will be selected from the Health Centers of Kashan University of Medical Sciences by Simple Random Sampling according to the inclusion and exclusion criteria. A trained nutritionist will enroll participants. Eligible participants will be stratified by age and BMI to ensure between-group homogeneity. Participants per stratum will be assigned to one of the two groups “modified intermittent fasting” (intervention) and “daily calorie restriction” (control) after baseline investigations. Individuals cannot be blinded to allocation because of the nature of the intervention. An independent statistician will generate the allocation sequence by using random numbers’ table and the statistician will be blinded throughout the entire trial.

We based our sample size calculation on fat-free mass (FFM) data of a previously published randomized controlled trial [17]. The mean and standard deviation of FFM were 63.4 and 3.4 (kg) in the intervention group and 66.9 and 4.9 (kg) in the control group. To detect a clinically significant difference in the outcome measures (sleep quality, daytime sleepiness, insomnia, BMI, FFM, body fat mass, waist circumference, waist-to-hip ratio, hip circumference, the visceral fat area, percent body fat, soft lean mass, skeletal muscle mass, extracellular water ratio, and total body water) with an alpha error of 5% and power of 80%, 23 women will be needed in each group. We presume a drop-out rate of 20%, based on clinical study experience, and thus 28 women will be recruited in each group.\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$n=\frac{{\left(Z1-\frac{\alpha }{2}+Z1-\beta \right)}^2\left({\sigma}_1^2+{\sigma}_2^2\right)}{\left({\mu}_1-{\mu}_2\right)}$$\end{document}n=Z1-α2+Z1-β2σ12+σ22μ1-μ2

We hypothesize that individuals with obesity or overweight will have more sleep disorders and that modified intermittent fasting diet will most benefit this group.

The primary outcomes of the study are the differences between the two groups with regard to the changes from baseline values in the following variables: Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Insomnia severity index, BMI, FFM, body fat mass, waist circumference, and the waist-to-hip ratio.

The secondary outcomes of the study are the differences between the two groups with regard to the changes from baseline values in the following variables: the hip circumference, the visceral fat area, the percent body fat, the soft lean mass, the skeletal muscle mass, the extracellular water ratio, and the total body water.

To control the adherence to the diet by the participants, once every 2 weeks, food record questionnaires will be completed 3 days (two normal days and one day off) a week. Researchers will make regular phone calls to participants to reinforce what they will be doing and to encourage them to continue. Also, participants will be monitored in weekly phone interviews. The data of subjects who discontinue or deviate from intervention protocols for any reason will be analyzed with intention-to-treat.

The criteria for discontinuing allocated interventions for a given trial participant include the following: calorie intake below 80% or above 110% of their recommended calorie, experiencing a severe emotional crisis during the study, and getting pregnant during the study.

This study will be conducted in Shahid Beheshti Hospital, Kashan. The trial will be run on an individual basis by the principal investigators. The study will be overseen by the scientific committee every week or when the need arises, in case of any adverse events. Kashan University of Medical Sciences will oversee the overall conduct of the trial. The study team will meet and discuss the problems in the operation of the study every week. DMC will be not needed for the study as the study will involve a small group of patients and will be in a single center.

Data will be stored in SPSS software and kept in local storage as well as in cloud storage. Although patients will have to provide their full names and contact details on the consent form, proper measures will be taken to protect their confidentiality. Their names will be replaced with a unique number that will be pasted onto their consent forms and their completed survey questionnaires. Results will be reported in aggregate. The data will not contain any personal information of the participants. Although every effort will be made to keep study records private, in some cases, patient information in this research study can be reviewed by representatives of the University for purposes such as quality control or safety.

The PSQI evaluates self-reported sleep disturbances and quality in the previous 4 weeks. PSQI measures 7 components of sleep and has 19 items: subjective sleep quality, sleep duration, sleep latency, use of sleeping medication, sleep disturbance, daytime dysfunction, and habitual sleep efficiency [20]. These items are rated in terms of the severity of the problem or frequency on a 4-point Likert scale (not during the past month: 0, less than once a week: 1, once or twice a week: 2, three or more times a week: 3). Each component score has a range of 0 to 3, with greater scores indicating lower sleep quality. The component scores sum yields a PSQI global score which ranges from 0 to 21. Higher scores express worse sleep quality. Statistical analyses also support looking at three factors, which include perceived sleep quality (using sleep latency, subjective sleep quality, and sleep medication variables), sleep efficiency (using sleep efficiency and sleep duration variables), and daily disturbances (using daytime dysfunctions and sleep disturbances variables). The PSQI has the same problems as other self-report inventories in that scores can be minimized or exaggerated by the person completing them [20].

The ESS measures daytime sleepiness. It is a self-reported questionnaire where individuals answer questions based on how likely they are to doze off or fall asleep during sedentary activities. It is an attractive alternative to objective methods of assessing sleepiness. ESS has eight items and includes a respondent format “would never doze” = 0, “slight chance of dozing” = 1, “moderate chance of dozing” = 2, and “high chance of dozing” = 3. A total score is calculated by summing the scores of the eight items, ranging from 1 to 24 points with higher values reflecting a higher level of sleepiness. The change score is calculated as the change between the total ESS score at baseline and follow-up [21].

The Insomnia Severity Index has seven items that evaluate the severity of sleep-onset (initial), early morning awakening (terminal) problems, sleep maintenance (middle), satisfaction with current sleep pattern, noticeability of impairment attributed to the sleep problem, interference with daily functioning, and level of distress caused by the sleep problem. Each item is rated on a 0–4 scale (0 indicating no problem and 4 indicating a very severe problem) with a total score ranging from 0 to 28. The Insomnia Severity Index total scores are categorized as 0–7: not clinically significant insomnia; 8–14: subthreshold insomnia; 15–21: moderate insomnia; and 22–28: severe insomnia [22].

The questionnaire of physical activity based on the metabolic equivalents (MET) will be used to measure physical activity in this study, which includes 9 levels of activity from sleep and rest (METs = 0.9) to intense activity (more than 6 METs) [23].

A stadiometer (accuracy of 0.5 cm) will be used to measure the Height. Individuals’ weight, with a light dress and without shoes, will be measured by using the scale (accuracy of 0.1 kg). BMI will be calculated as weight (kg) divided by height squared (m²). The waist-to-hip ratio will be calculated as the waist circumference divided by the hip circumference. The waist circumference will be measured at the midpoint between the iliac crest and lowest rib, by using a non-stretchable measuring tape during normal expiration [24]. The hip circumference will be horizontally measured at the widest portion of the buttocks [24]. Other anthropometric indices such as extracellular water ratio, visceral fat area, percent body fat, fat-free mass, body fat mass, soft lean mass, skeletal muscle mass, and total body water will be evaluated by Inbody770 model BPM040S12FXX. All anthropometric indices will be measured at the beginning and end of the study.

To investigate if the data follows a normal distribution, we will use the Kolmogorov-Smirnov test. To compare qualitative data between the two groups, a chi-square test will be used. An independent t-test will be used to determine differences in quantitative data between groups. In non-parametric conditions and parametric conditions, the Wilcoxon test and paired t-test, respectively, will be used to compare the mean of quantitative variables within the group before and after the intervention. To compare the mean between the two groups, the Mann-Whitney test and t-test for non-parametric conditions and parametric conditions, respectively, will be used. Analysis of covariance will be utilized to determine the difference in data changes between the 2 groups at the end of the study. The adjusted p-values corresponding to each statistical test will be used to investigate the intervention effects by using the Bonferroni correction to analyze multiple outcomes. Data analysis will be done with SPSS software. We plan to conduct two subgroup analyses, both with strong biological rationale and possible interaction effects. Multiple regression model and analysis of covariance (ANCOVA) will be used to evaluate whether specific variables are confounders for the treatment effect and whether the treatment effect interacts with specific covariates.

We propose to use two analysis sets; the intention-to-treat set, considering all patients as randomized regardless of whether they received the randomized treatment, and the “per protocol” analysis set. Given our expectation that very few patients will crossover or be lost to follow-up, these analyses should agree very closely. We will report reasons for withdrawal for each randomization group and compare the reasons qualitatively. The effect that any missing data might have on results will be assessed via sensitivity analysis of augmented data sets. Dropouts (essentially, participants who withdraw consent for continued follow-up) will be included in the analysis by regression imputation method for missing data. This will be accomplished using a set of repeated imputations created by predictive models based on the majority of participants with complete data. After the imputations are completed, all of the data (complete and imputed) will be combined and the analysis performed for each imputed-and-completed dataset. Rubin’s method of multiple (i.e., repeated) imputation will be used to estimate the treatment effect. No interim analyses will be performed.

Adverse events if any, which are directly related to the study intervention, will be monitored and assessed by researchers involved in the study. The patient will be on continuous monitoring. Any such adverse events that arise during the study will be reported to Kashan University of Medical Sciences and the Ethics Committee of Kashan University of Medical Sciences. Any such events will be managed by the treating physician and the cost for the same will be covered under the trial fund.

The study team will meet every week and will conduct at least one on-site visit every week to check the quality of the data, database operation, subject material, and informed consent. This team, totally independent from the authors and competing interests, will have the full right to make the final decision on the trial status.

Any change in the conductance of the study made in the protocol will be informed in the specified format to Kashan University of Medical Sciences and the IRCT. As the study has followed up, the patients who will be present in the study will be informed about the protocol changes.